In the technology transfer process, after analyzing the state of the art, it is crucial to study the commercial state. This market study allows us to understand the commercial viability of new technologies, identify potential market segments and evaluate existing competition. Furthermore, it provides a comprehensive view that complements the technical evaluation, ensuring that innovations are not only technically viable, but also commercially successful.
The global precision medicine market was valued at $73.49 billion in 2022 and is estimated to reach $81.03 billion in 2024, with projections of $104.40 billion in 2029. This reflects a rate compound annual growth of 5.20%. By 2030, the market is expected to reach $175.64 billion. The precision pharmacology market, valued at $24.4 billion in 2022, shows compound annual growth of 13.2% through 2030.
Relevant Companies in the Sector Worldwide.
This analysis of the global competitive landscape was carried out based on the exhaustive report “Analysis of participation and size of the precision medicine market, trends and growth forecasts (2024-2029)”, carried out by international companies.
- Pfizer (USA)
- Medtronic (Ireland)
- Novartis (Switzerland)
- Qiagen (Germany)
- Thermo Fisher (USA)
Relevant Companies in the Sector at a Regional Level.
The same methodology was used to determine the main actors in the region, therefore they are not necessarily Latin American companies, but rather, those that stand out in the competitive environment of the region.
- Living DNA (USA)
- GeneType (Australia)
- Exame Group (Brazil)
- Genomika (Brazil)
